Department of General Surgery, First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Chin Med J (Engl). 2013;126(17):3371-4.
This review focuses on the state-of-the-art of CXCL12/CXCR4 signaling axis in pancreatic cancer and its role in tumor progression.
Relevant articles published in English were identified by searching in Pubmed from 1997 to 2013, with keywords "CXCL12", "CXCR4" and "pancreatic cancer". Important references from selected articles were also retrieved.
Articles about CXCL12/CXCR4 signaling axis in pancreatic cancer and relevant mechanisms were selected.
Pancreatic cancer has been one of the most lethal human malignancies, with median survival less than one year and overall 5-year survival only 6%. Tumor cells from pancreatic cancer express high level of CXCR4. CXCL12, the ligand for CXCR4, is extensively secreted by neighboring stromal cells and other distant organs. CXCL12 primarily binds to CXCR4, induces intracellular signaling through several divergent pathways, which are involved in progression and metastasis of pancreatic cancer.
CXCL12/CXCR4 signaling axis may play an important role in the communication between pancreatic cancer cells and their microenvironment, which may have effect on tumor proliferation, invasion, angiogenesis, metastasis and chemoresistance. CXCL12/CXCR4 signaling axis may serves as a novel therapeutic target for pancreatic cancer.
本综述重点探讨了趋化因子(C-X-C)配体 12/趋化因子受体 4(CXCL12/CXCR4)信号轴在胰腺癌中的最新研究进展及其在肿瘤进展中的作用。
通过在 Pubmed 中检索 1997 年至 2013 年发表的英文相关文章,使用“CXCL12”、“CXCR4”和“胰腺癌”作为关键词,确定了相关文章。还检索了选定文章中的重要参考文献。
选择了关于胰腺癌中 CXCL12/CXCR4 信号轴及其相关机制的文章。
胰腺癌是最致命的人类恶性肿瘤之一,中位生存期不到一年,总体 5 年生存率仅为 6%。胰腺癌肿瘤细胞表达高水平的 CXCR4。趋化因子(C-X-C)配体 12(CXCL12)是 CXCR4 的配体,广泛由邻近的基质细胞和其他远处器官分泌。CXCL12 主要与 CXCR4 结合,通过几种不同的途径诱导细胞内信号转导,这些途径参与了胰腺癌的进展和转移。
CXCL12/CXCR4 信号轴可能在胰腺癌细胞与其微环境之间的通讯中发挥重要作用,这可能对肿瘤增殖、侵袭、血管生成、转移和化疗耐药性产生影响。CXCL12/CXCR4 信号轴可能成为胰腺癌的一个新的治疗靶点。